Phenom Recognized as a Strategic Leader in Fosway’s 2022 9-Grid™ for Talent Acquisition for Second Consecutive Year
4.5.2022 16:36:00 EEST | Business Wire | Press release
Phenom, the leading AI-powered talent experience platform, has been named a Strategic Leader in the 2022 Fosway 9-Grid™ for Talent Acquisition for the second year in a row. Fosway identifies Strategic Leaders as companies that provide a rich suite of capability across a broad scope of features and have the sophistication to consistently meet the needs of complex enterprise-scale customers. According to Fosway, Phenom has proven its ability to deliver higher levels of innovation, customer impact and advocacy compared to alternatives in the market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220503006092/en/
Phenom positioned as Strategic Leader in Fosway 9-Grid (Graphic: Business Wire)
With the highest job vacancy rate Europe has seen in 14 years, the talent shortage has developed into a crisis that extends far beyond human resources. To better connect with candidates and quickly fill open roles, CHROs and CEOs from today’s leading enterprises are choosing systems of intelligence to automate tasks and provide personalised experiences that job seekers expect in today’s competitive talent market.
Phenom’s position as a Strategic Leader reinforces that its Talent Experience Management (TXM) platform is enabling enterprises with the AI and automation necessary to quickly identify and hire best-fit talent, and an intelligent talent marketplace to develop and retain their best employees.
“Organisations are facing acute recruitment challenges that require innovative approaches to talent acquisition," said David Wilson, CEO, Fosway Group. "Phenom has consolidated its position as a Strategic Leader on the 2022 Fosway 9-Grid™ for Talent Acquisition through its focus on innovation and harnessing talent intelligence to deliver better recruitment outcomes for customers."
In 2021, 50,000 recruiters, talent marketers and hiring managers used Phenom to hire over 2 million people and engage over 5 million employees. Built on a vast network of data, contextual industry models and deep learning, the Phenom TXM platform is empowering organisations to:
- Engage & hire best-fit candidates faster: Connecting job seekers with relevant job recommendations and content based on skills, experience and location with a personalised Career Site, conversational Chatbot and CMS.
- Improve recruiter productivity: Identifying best-fit talent for open roles and automating tedious administrative tasks with a talent CRM, Campaigns, AI Scheduling, Video Assessments and AI Insights.
- Develop and retain employees: Fostering employee engagement, growth, and retention with an Internal Talent Marketplace, Career Pathing, Internal Mobility, Gigs, Diversity, Equity & Inclusion and Employee Resource Groups.
- Enable hiring managers: Streamlining collaboration with managers and elevating meaningful insights through talent analytics.
AXA, a global insurance company and Phenom customer, continues to see new value in the Phenom platform every day.
“With Phenom, it’s easier than ever for employees and candidates to explore open jobs across our organisation. Since the platform is constantly capturing and analyzing data, it’s delivering personalized experiences to help everyone find the right fit. When we’re able to connect people with opportunities where they can shape the way they work and realize their potential, that’s the greatest achievement of all,” said Amanda Vaughan, Global Head of Talent & Learning at AXA.
“As enterprises rely on talent experience to meet hiring demands in EMEA, maintaining our position as a Strategic Leader in Fosway’s Talent Acquisition grid signifies how we’re planting our roots in the HR technology market,” said Jeff Carey, senior vice president of international business at Phenom. “Our customers chose Phenom as the AI-powered solution to not only help them find candidates faster and retain talent today — they’re also investing in our constant innovation to ensure they’re future-proofed for the inevitable demands that will arise tomorrow.”
Companies across EMEA are successfully adopting Phenom’s talent experience platform to help candidates find the right job faster, recruiters discover best-fit talent, employees learn and evolve and managers build their teams. To support the growing need for Talent Experience Management, Phenom acquired three Europe-based companies and now has employees based in countries including Germany, France, Ireland, the Netherlands, Switzerland, Italy, Spain and the United Kingdom.
To learn more about Phenom’s Strategic Leader position, please visit their blog.
To see Fosway’s full analysis, check out their 2022 9-grid™.
About Phenom
Phenom is a global HR technology company with a purpose to help a billion people find the right job. With an expertise in building AI-powered, scalable solutions, Phenom Talent Experience Management (TXM) personalises and automates the talent journey for candidates, recruiters, employees and managers with its Career Site, Chatbot, CRM, CMS, SMS and Email Campaigns, University Recruiting, Internal Mobility, Career Pathing, Diversity & Inclusion, Talent Marketplace, Gigs, Referrals, Hiring Manager and Analytics. As a result, employers improve their talent acquisition and talent management efforts by helping candidates find the right job, employees grow and evolve, recruiters discover top talent, and managers build teams faster. Phenom was a winner in the Business Intelligence Group’s 2021 Artificial Intelligence Excellence Awards program for its sophisticated machine learning capabilities and was ranked among the fastest-growing private companies in the 2021 Inc. 5000.
Headquartered in Greater Philadelphia, Phenom also has offices in India, Israel, the Netherlands, Germany and the United Kingdom.
For more information, please visit www.phenom.com. Connect with Phenom on LinkedIn, Twitter, Facebook, YouTube and Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220503006092/en/
Contact information
Media:
Jennifer Lyons
Director, Global Communications
267-379-5066
jennifer.lyons@phenompeople.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom